New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
Open Access
- 15 May 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 114 (1), 1-11
- https://doi.org/10.1007/s11060-013-1151-1
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotideDiabetes & Metabolism, 2013
- Medical management of Cushing’s disease: what is the future?Pituitary, 2012
- EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasJCI Insight, 2011
- Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomasBMC Endocrine Disorders, 2010
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus StatementJournal of Clinical Endocrinology & Metabolism, 2008
- Somatostatin and somatostatin receptors in Cushing's diseaseMolecular and Cellular Endocrinology, 2007
- Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonistsMovement Disorders, 2007
- Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Patients with Cushing's Disease Secrete Adrenocorticotropin and Cortisol Jointly More Asynchronously than Healthy SubjectsJournal of Clinical Endocrinology & Metabolism, 1998
- The effect of somatostatin and of prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cellsLife Sciences, 1977